Semax vs. N-Acetyl-Semax vs. Adamax: The Complete Nootropic Peptide Guide
Semax, N-Acetyl-Semax, and Adamax represent three generations of the same foundational research peptide — each built on the heptapeptide sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) derived from the adrenocorticotropin hormone (ACTH) fragment 4-7. Each modification improves on the last in terms of enzymatic stability, CNS bioavailability, or receptor interaction kinetics. Understanding the differences between them is essential for researchers selecting the appropriate tool for BDNF upregulation, TrkB modulation, or neuroprotection studies.
Semax: The Original ACTH-Derived Nootropic
Semax (CAS 80714-61-0) is a synthetic 7-amino-acid peptide designed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. Its sequence combines the ACTH(4-7) tetrapeptide (Met-Glu-His-Phe) — the minimal bioactive fragment that retains the nootropic and neurotrophin-modulating activity of ACTH — with a C-terminal Pro-Gly-Pro tripeptide that resists the brain peptidases (pyroglutamyl aminopeptidase and prolyl endopeptidase) that would rapidly degrade a shorter sequence.
Semax increases hippocampal and cortical BDNF (brain-derived neurotrophic factor) mRNA and protein expression in preclinical models. BDNF acts through TrkB (NTRK2) receptors to promote neuronal survival, synaptic plasticity, and long-term potentiation. Semax also activates serotonergic and dopaminergic neurotransmission and has been studied in Russian clinical literature for ischemic stroke and optic nerve disease — though it remains unapproved outside Russia.
N-Acetyl-Semax: Stability Improvement at the N-Terminus
N-Acetyl-Semax adds an acetyl group (CH₃CO—) to the N-terminus of the Semax heptapeptide, converting the free amino group to an acetamide. This single modification meaningfully improves the compound’s pharmacological profile: the N-acetyl group protects against aminopeptidase cleavage at the Met-1 position — the primary enzymatic attack point for N-terminally exposed peptides in plasma and brain tissue. The result is improved systemic and CNS stability compared to non-acetylated Semax.
N-Acetyl-Semax also shows altered receptor interaction kinetics relative to Semax — the N-terminal modification changes the peptide’s charge distribution and hydrogen-bonding profile at the receptor interface, which some researchers report as changes in potency and duration relative to the parent compound. As with Semax, CNS delivery is most efficient via nasal route in standard protocols due to the peptide’s hydrophilicity limiting passive BBB diffusion.
Adamax: Adamantane-Enhanced CNS Delivery
Adamax is the most advanced form — N-Acetyl-Semax with the addition of an adamantane (tricyclodecane, C₁₀H₁₆) moiety. The adamantane scaffold is a rigid, cage-like polycyclic hydrocarbon that appears across CNS pharmacology as a BBB-penetration enhancer: amantadine (antiparkinsonian), memantine (Alzheimer’s NMDA antagonist), and rimantadine all use the adamantane scaffold. Its lipophilic rigidity increases the overall logP of the conjugate, facilitating enhanced passive transcellular diffusion across brain endothelial cell membranes.
For peptide research specifically, this matters because peptides are inherently hydrophilic — their hydrogen-bonding capacity and polarity make BBB crossing via passive diffusion inefficient. By conjugating the adamantane cage to the N-Acetyl-Semax backbone, Adamax becomes substantially more lipophilic, enabling systemic administration with greater CNS bioavailability than either Semax or N-Acetyl-Semax achieves. The BDNF upregulation and TrkB activation that are the primary research endpoints of the Semax family become accessible at higher central concentrations.
Comparison Table: Semax Variant Family
| Property | Semax | N-Acetyl-Semax | Adamax |
|---|---|---|---|
| Sequence | MEHFPGP | Ac-MEHFPGP | Ac-MEHFPGP + adamantane |
| N-terminal Protection | No | Yes (acetyl) | Yes (acetyl) |
| BBB Penetration | Moderate (nasal route) | Moderate | Enhanced (lipophilic scaffold) |
| Systemic Stability | Low | Improved | High (dual stabilization) |
| Primary Research Focus | Nootropic, BDNF, stroke | BDNF enhancement, nootropic | CNS delivery, BDNF/TrkB, neuroprotection |
| Relative CNS Bioavailability | Baseline | Moderate improvement | Highest of the three |
Frequently Asked Questions
Which is better for research: Semax or Adamax?
It depends on the research question. Semax has the most published literature and is the historical reference compound. Adamax is the most CNS-delivery-optimized of the three, making it preferable for protocols requiring systemic administration with maximum central BDNF/TrkB engagement. Researchers comparing them directly will need to account for the different delivery efficiency when designing dosing protocols.
What is the BDNF/TrkB pathway and why does the Semax family affect it?
BDNF (brain-derived neurotrophic factor) is the primary ligand for TrkB (NTRK2), a receptor tyrosine kinase mediating neuronal survival, synaptic plasticity, and memory consolidation via PI3K/Akt, MAPK/ERK, and PLC-gamma cascades. Semax and its analogs upregulate BDNF gene expression in the hippocampus and cortex, increasing endogenous TrkB activation — positioning them as indirect TrkB pathway activators rather than direct receptor agonists.
Is Adamax approved for human use?
No. Adamax is a research compound with no regulatory approval in any jurisdiction. It is supplied for laboratory and in vitro research applications only.
